Buradasınız

Takrolimusa Bağlı Posterior Geri Dönüşümlü Ensefalopati Sendromu (PRES)

Tacrolimus-Induced Posterior Reversible Encephalopathy Syndrome (PRES)

Journal Name:

Publication Year:

DOI: 
10.5262/tndt.2014.1003.17
Abstract (2. Language): 
Since solid organ and hematopoietic stem cell transplantations have been performed increasingly recently, use of immunosuppressive agents such as cyclosporine and tacrolimus has also risen significantly. Posterior reversible encephalopathy syndrome (PRES) is known to be a serious complication of immunosuppressive therapy use following solid organ or stem cell transplants. Clinical findings of the syndrome involve headache, mental status changes, focal neurological deficits, as well as visual disturbances, which are also associated with characteristic imaging features of subcortical white matter lesions on computed tomography (CT) or magnetic resonance imaging (MRI). Despite the fact that the alterations in subcortical white matter might be secondary to potentially reversible vasogenic edema, conversion to irreversible cytotoxic edema has also been described. These imaging findings appear to be prevalent in the territory of the posterior cerebral artery. In most earlier studies, it has been reported that the neurotoxicity associated with tacrolimus may occur at therapeutic levels. The sypmtom complex in most cases in PRES can be reversed through decreasing the dosage or withholding the drug for a few days. PRES is an uncommon complication; however, it may lead to significant morbity and mortality if ir is not diagnosed instantly. The study sheds light on the importance of MRI in prompt recognition of this syndrome, which provides us with the best chance to avoid long-run sequelae. This report highlights the value of MRI in prompt recognition of this entity, which offers the best chance of avoiding long-term sequelae. We aimed to present our 9 year-old renal transplant patient in whom we observed PRES following tacrolimus treatment in the light of clinical and MRI findings. Similar findings did not recur after tacrolimus use. Drug was not changed.
Abstract (Original Language): 
Solid organ ve hematopoetik kök hücre nakli artan sayıda yapılmaktadır. Bu nedenle siklosporin ve takrolimus gibi immünsupresif ajanların kullanımında önemli artışlar olmuştur. Posterior geri dönüşümlü ensefalopati sendromu (PRES) solid organ veya kök hücre nakli sonrasında immünsupresif tedavi kullanımının ciddi bir komplikasyonudur. Baş ağrısı, mental durum değişiklikleri, fokal nörolojik ve/veya görme bozuklukları gibi klinik bulgular görülmektedir. Bilgisayarlı tomografi (BT) veya manyetik rezonans görüntüleme (MRG) subkortikal beyaz cevher lezyonlarına ait karakteristik görüntüleme bulguları vardır. Subkortikal beyaz cevher değişiklikleri, geri dönüşümlü vazojenik ödeme veya geri dönüşümü olmayan sitotoksik ödem ikincil olarak görülebilir. Bu görüntüleme bulguları posterior serebral arter kanlanma bölgelerinde görülür. Birçok çalışma, takrolimus nörotoksisite ile ilişkili terapötik seviyelerde ortaya olabileceğini göstermiştir. PRES septomları çoğu durumda, ilaç dozunun azaltılması ya da birkaç gün boyunca ilaç yapılmayarak tersine çevrilebilir. PRES nadir bir komplikasyon olmasına rağmen süratle önemli morbidite ve mortalite ile ilişkilidir. MR PRES tanımak için en hassas görüntüleme tekniğidir. Takrolimus tedavisi sonrasında PRES gözlemlediğimiz 9 yaşındaki renal transplant olgumuzu klinik ve MRI bulguları eşliğinde sunmak istedik. Benzer bulgular ilaç kullanımından sonra tekrarlamadı. İlaç değiştirilmedi.
265
268

REFERENCES

References: 

1. Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti
C, Forman AD, Kumar AJ, Champlin R, Couriel D: Tacrolimusassociated
posterior reversible encephalopathy syndrome after
allogenic hematopoietic stem cell transplantation. Br J Haematol
2003;122:128-134
2. Eidelman BH, Abu-Elmagd K, Wilson J, Fung JJ, Alessiani M,
Jain A, Takaya S, Todo SN, Tzakis A, Van Thiel D: Neurologic
complications of FK-506. Transplant Proc 1991; 23:3175-3178
3. Hauser RA, Lacey DM, Knight MR: Hypertensive encephalopathy:
Magnetic resonance imaging demonstration of reversible cortical
and white matter lesions. Arch Neurol 1998; 45:1078-1083
4. Nakamura M, Fuchinoue S, Sato S, Hoshino T, Sawada T,
Sageshima J, Kitajima K, Tojinbara T, Fujita S, Nakajima I, Agishi
T, Tanaka K: Clinical and radiological features of two cases of
tacrolimus-related posterior leukoencephalopathy in living related
liver transplantation. Transplant Proc 1998; 30:1477-14785. Jarosz JM, Howlett DC, Cox TC, Bingham JB: Cyclosporine- related
reversible posterior leukoencephalopathy. MRI Neuroradiology
1997; 39:711-715
6. Ito Y, Arahata Y, Goto Y, Hirayama M, Nagamutsu M, Yasuda T,
Yanagi T, Sobue G: Cisplatin neurotoxicity presenting as reversible
posterior encephalopathy syndrome. AJNR Am J Neuroradiol 1998;
19:415-417
7. Delanty N, Vaughan C, Frucht S, Stubgen P: Erythropoietinassociated
hypertensive leukoencephalopathy syndrome. Neurology
1997; 49:686-689
8. Trommer BL, Homer D, Mikhel MA: Cerebral vasospasm and
eclampsia. Stroke 1988; 19:326-329
9. Covarrubias DJ, Luetmer PH, Campeau NG: Posterior reversible
encephalopathy syndrome: Prognostic utility of quantitative
diffusion weighted MR images. AJNR Am J Neuroradiol 2002;
23:1038-1048
10. Casey SO, Sampaio RC, Michel E, Truwit CL: Posterior reversible
encephalopathy syndrome: Utility of FLAIR imaging in the detection
of cortical and subcortical lesions. AJNR Am J Neuroradiol 2000;
21:1199-1206
11. Provenzale JM, Petrella JR, Cruz LC Jr, Wong JC, Engelter S,
Barboriak DP: Quantitative assessment of diffusion abnormalities
in posterior reversible encephalopathy syndrome. AJNR Am J
Neuroradiol 2001; 22:1455-1461
12. Bartynski WS. Posterior reversible encephalopathy syndrome,
fundamental imaging and clinical features. AJNR Am J Neuroradiol
2008;29(6):1036-1042

Thank you for copying data from http://www.arastirmax.com